Gileady announced it would discontinue its hepatitis C vaccines in July, citing the company’s continued inability to obtain enough clinical trials to prove the vaccine’s safety.
The announcement came amid an escalating debate over the efficacy of the vaccines, which were first approved by the FDA in 1996.
The FDA has said that it is now waiting for a clinical trial of the hepatitis C vaccine, which is being offered through a partnership with Gileado Pharmaceuticals, a company that makes Gileadex.
But Gileader is still holding onto the vaccine, and some in Congress have argued that Gileada should be allowed to keep selling it.
On Thursday, Rep. Steve King, R-Iowa, asked the FDA to require Gileadan to stop making the vaccine if it is still selling it in the United States.
King, who is a co-sponsor of the Government Shutdown Prevention Act, a bill that would require Congress to stop funding the FDA until the agency takes action on the hepatitis vaccine, said Gileadin should “immediately” stop selling it to the public.
“The only way that this vaccine will be available for people to use and get vaccinated against hepatitis C is if Gileadal is forced to stop selling the hepatitis A vaccine in the U.S.,” King said in a statement.
On Thursday, the CDC also released a statement saying that the agency is not recommending that the vaccine be sold to the general public.
“We continue to believe that the current vaccine does not meet the CDC’s clinical safety and efficacy criteria,” the CDC said.
“We are pleased to have the CDC in support of our efforts to reduce the prevalence and transmission of hepatitis, and we look forward to working with them in the coming weeks,” Gileades said in the statement. “
Additionally, the vaccine has not been shown to be safe in clinical trials.”
“We are pleased to have the CDC in support of our efforts to reduce the prevalence and transmission of hepatitis, and we look forward to working with them in the coming weeks,” Gileades said in the statement.
“Our continued focus on making vaccines available for the public, while still meeting the CDC recommendations, allows us to be in a position to deliver the vaccines to patients at the earliest opportunity.”